Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions.

This review looks at current autism treatments and research gaps. While there are no medications specifically for autism's main symptoms (communication, social skills, repetitive behaviors), doctors can prescribe medications for related issues like aggression, ADHD, and sleep problems. The authors stress that better diagnostic tests and personalized treatments are urgently needed to help children with autism more effectively.

This 2024 review examines current autism research limitations and pharmacological interventions for children with ASD. The authors highlight that ASD is characterized by three core impairments: communication difficulties, social interaction challenges, and restricted/repetitive behaviors, with common comorbidities including ADHD, anxiety, depression, and epilepsy. Currently, no medications are approved for treating core ASD symptoms, with behavioral interventions serving as first-line treatment. However, several psychotropic medications are approved for managing associated symptoms: aripiprazole, risperidone, and haloperidol for irritability/aggression; methylphenidate, atomoxetine, clonidine, and guanfacine for ADHD; and melatonin for sleep issues.

The review emphasizes the critical need for objective diagnostic tools and personalized treatment approaches to improve clinical outcomes.

Clinicians should prioritize behavioral interventions for core ASD symptoms while considering targeted pharmacological treatments for specific comorbidities. The review supports evidence-based prescribing of approved medications for irritability, ADHD, and sleep issues, while highlighting the urgent need for objective diagnostic tools and personalized treatment strategies in autism care.

As a review article, this study synthesizes existing literature rather than presenting new research data. The abstract does not specify search methodology, inclusion criteria, or quality assessment of reviewed studies, limiting evaluation of comprehensiveness and potential bias.

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by three core impairments: impaired communication, impaired reciprocal social interaction, and restricted, repetitive, and stereotypical behavior patterns. Spectrum refers to the heterogeneity of presentation, severity of symptoms, and medical comorbidities associated with ASD. Among the most common underlying medical conditions are attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, epilepsy, digestive disorders, metabolic disorders, and immune disorders. At present, in the absence of an objective and accurate diagnosis of ASD, such as a blood test, pharmacological management remains a challenge.

There are no approved medications to treat the core symptoms of the disorder and behavioral interventions are typically used as first line treatment. Additionally, psychotropic drugs with different mechanisms of action have been approved to reduce associated symptoms and comorbidities, including aripiprazole, risperidone, and haloperidol for irritability and aggression, methylphenidate, atomoxetine, clonidine, and guanfacine for ADHD, and melatonin for sleep disturbances. The purpose of this review is to emphasize that it is imperative to develop objective, personalized diagnostic kits in order to tailor and individualize treatment strategies, as well as to describe the current pharmacological management options available in clinical practice and new prospects that may be helpful in managing ASD's core symptoms.